It involves collecting safety and efficacy data, under the actual conditions of use of off label and compassionate use medicines in children and adolescents approved in humans before 2007, using a validated tool (Ennov EDC) and relying on the network recognised pediatric hemato-oncology centers in Belgium and responsible for the organization of Pediatric National tumor boards which discuss each case of relapse in order to define the best therapeutic options.
Inclusion Criteria:
Exclusion Criteria:
Any child, adolescent or young adult, treated for a pediatric tumor or leukemia, in therapeutic failure or relapse without standard treatment option, not eligible / refusal of inclusion in a clinical study open on the territory and treated with an innovative drug within the framework of a compassionate use or outside marketing authorization, in one of the centers of the Belgian pediatric hemato-oncology centers
Antwerp, 2650, Belgium
toon.vangenechten@uza.be+32 3 821 58 58
Securing Access to Innovative Molecules in Oncology and Hematology for Children, Adolescents and Young Adults
Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO)
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Proof -of -Concept Study To Stratify Targeted Therapies Adapted To Molecular Profiling
Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer
Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma
Organoid-based Sensitivity-guided Chemotherapy for Advanced / Refractory Pediatric Tumors
Active Pharmacovigilance of Anti-cancer Medicines